anonymous
Guest
anonymous
Guest
Companies of this size are not built to become profitable they are built to show revenue and then get sold. If MF and Endo read out this will create a revenue flow that would be attractive to acquiring companies. If not, it’s over.
Bottom line there is enough money and time now to get both trials read out and filed.
All the other afore mentioned financial mechanics really don’t matter at this point.
Of note, this restructuring of debt is common place in small cap biotech with promising data.
You seriously need to stop with the "promising data" BS, you have no idea what the data says nor do the debt holders, public companies CANNOT give private previews of data to investors whether they be stockholders or debt holders. If you have ever been in a data rollout, there are even severe restrictions on people within the company about who can see data prior to making it public and penalties for violation are no joke, disbarment, fines and potentially prison. And as pointed out above, debt holders agreed to the restructure, because it was the best option in a series of terrible options.